Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumour in humans and has a very poor prognosis. The existing treatments have had limited …

The blood–brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal
brain. However, the importance of the BBB in limiting drug delivery and efficacy is …

The impact of targeted therapies in glioma has been modest. All the therapies that have
demonstrated a significant survival benefit for gliomas in Phase III trials, including radiation …

Simple Summary Glioblastoma is the most common and aggressive malignant primary brain
cancer in adults. The prognosis remains poor following standard-of-care treatment with …

Abstract Each year, about 5–6 cases out of 100,000 people are diagnosed with primary
malignant brain tumors, of which about 80% are malignant gliomas (MGs). Glioblastoma …

Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …

Glioblastoma multiforme (GBM) is a debilitating disease that is associated with poor
prognosis, short median patient survival and a very limited response to therapies. GBM has …

Abstract Antibody–drug conjugates (ADCs), a class of targeted cancer therapeutics
combining monoclonal antibodies with a cytotoxic payload via a chemical linker, have …

Standard treatment for glioblastoma multiforme is surgery followed by radiotherapy and
chemotherapy, generally with temozolomide. However, disease recurs in almost all patients …